Vertex Pharmaceuticals (NASDAQ:VRTX) is a top biotech stock with a Buy rating and $478 price target. Analyst sees potential in kidney franchise and innovative treatments for diseases like membranous nephropathy. Company develops medicines for rare diseases like cystic fibrosis and sickle cell disease.